On September 24, Viking Therapeutics rose 5.31% in regular trading, trading at $42.94/share, with turnover of $513 million. The stock continued to build on momentum following the company's release of positive topline data from its GLP-1/GIP dual agonist VK2735 maintenance study.

The data, initially disclosed on September 22 and triggering a single-day surge of over 30%, showed that patients switching from weekly to biweekly dosing preserved up to 97% of their initial weight loss, while those on monthly maintenance doses retained approximately 85% — compared to just 61% for the placebo group. Under the weekly 17.5mg regimen, placebo-adjusted weight reduction reached 22% at week 33. Citi analyst Geoff Meacham highlighted that the ability to maintain weight loss with fewer injections is what truly distinguishes these findings. The company plans to explore oral dosing regimens in the next phase of the study.

Viking Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and endocrine disorders. Its lead obesity candidate VK2735 is being developed in both injectable and oral formulations.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)